CD19 and cancer: We next assayed for FRα protein expression on residual tumors after treatment with untransduced, anti-CD19 CAR or FRα-specific CAR T cells, to determine whether tumor outgrowth in FRα CAR-treated mice was a byproduct of immune pressure and selective growth of FRα-negative cancer cells.